CVRx (CVRX)
NASDAQ:CVRX
CVRX Stock Chart & Stats
$8.51
-$0.03(-0.21%)
At close: 4:00 PM EST
$8.51
-$0.03(-0.21%)
Day’s Range― - ―
52-Week Range$4.30 - $13.15
Previous CloseN/A
Volume20.10K
Average Volume (3M)197.28K
Market Cap
$223.91M
Enterprise Value$198.99M
Total Cash (Recent Filing)$75.71M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Apr 29, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding26,311,607
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit4.12
Enterprise Value/Ebitda-4.18
Forecast
1Y Price Target
$11.00Price Target Upside29.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.01
Revenue Forecast (FY)$64.72M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionCMS Category B coverage for the BENEFIT-HF trial enables enrollment and, if the study is successful, could significantly expand the company's addressable market and raise awareness among cardiology specialists.
Reimbursement And Billing ImprovementsImplementation of Category I CPT codes combined with potential public payer coverage for trial patients should reduce reimbursement friction and improve commercial access, creating a meaningful revenue tailwind.
Revenue Outperformance And Guidance AlignmentReported quarterly revenue came in ahead of expectations and management's revenue guidance for 2026 aligns with analyst estimates, signaling improving utilization and accelerating business momentum.
Bears Say
Increased Leverage And Liquidity ConcernsThe company amended and drew on its term loan facility, increasing leverage and extending an interest-only period under relatively high interest terms, which raises financial risk and investor concern about liquidity.
Rising Operating Expenses And Cash-flow RiskManagement's guidance implies a substantial planned increase in operating expenses, making cash-flow breakeven more difficult and increasing uncertainty around near-term profitability.
Salesforce DisruptionSalesforce reorganization has disrupted accounts and left representatives below expected productivity, hindering expansion into new centers and weighing on commercial execution.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.30 and its highest was $13.15 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $223.91M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Apr 29, 2026 which is in 34 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Feb 12, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.439 by -$0.021.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.52.
How many shares outstanding does CVRx have?
CVRx has 26,311,607 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.439. Following the earnings report the stock price went down -13.005%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (29.26% Upside)
$11.00 (29.26% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $183.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
-99.33%
Trailing 12-Months
Asset Growth
-21.45%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights important commercial and reimbursement milestones (Category I CPT code, improved prior authorization rates), stronger gross margins and a major clinical trial (BENEFIT HF) that can materially expand the addressable market long-term. These positives are balanced against continued net losses, sizable and growing operating expense guidance, expected cash burn in 2026, and near-term revenue growth that remains modest as a larger sales organization continues to ramp. Management emphasizes building durable programs and long-term growth rather than short-term profitability.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$11.00
▲(29.26% Upside)
Technical Analysis
Ownership Overview
28.73% Insiders
6.63% Mutual Funds
33.08% Other Institutional Investors
25.43% Public Companies and
Individual Investors